• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates

tetano

Editor, Senior Moderator
Beilstein J Nanotechnol. 2019 May 14;10:1038-1047. doi: 10.3762/bjnano.10.104. eCollection 2019.
[h=1]Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates.[/h] Alghrair ZK[SUP]1,[/SUP][SUP]2[/SUP], Fernig DG[SUP]1[/SUP], Ebrahimi B[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The influenza ("flu") type-A virus is a major medical and veterinary health concern and causes global pandemics. The peptide "FluPep" is an established inhibitor of influenza virus infectivity in model systems. We have explored the potential for noble-metal nanoparticle conjugates of FluPep to enhance its antiviral activity and to determine their potential as a delivery platform for FluPep. FluPep ligand is FluPep extended at its N-terminus with the sequence CVVVTAAA, to allow for its incorporation into a mixed-matrix ligand shell of a peptidol and an alkanethiol ethylene glycol consisting of 70% CVVVTol and 30% HS(CH[SUB]2[/SUB])[SUB]11[/SUB](OC[SUB]2[/SUB]H[SUB]4[/SUB])[SUB]4[/SUB]OH (mol/mol). Gold and silver nanoparticles (ca. 10 nm diameter) with up to 5% (mol/mol) FluPep ligand remained as stable as the control of mixed-matrix-passivated nanoparticles in a variety of tests, including ligand exchange with dithiothreitol. The free FluPep ligand peptide was found to inhibit viral plaque formation in canine MDCK cells (IC[SUB]50[/SUB] = 2.1 nM), but was less potent than FluPep itself (IC[SUB]50[/SUB] = 140 pM). Nanoparticles functionalised with FluPep ligand showed enhanced antiviral activity compared to the free peptides. The IC[SUB]50[/SUB] value of the FluPep-functionalised nanoparticles decreased as the grafting density of FluPep ligand increased from 0.03% to 5% (both mol/mol), with IC[SUB]50[/SUB] values down to about 10% of that of the corresponding free peptide. The data demonstrate that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of silver ions may enable the design of even more potent antimicrobial inhibitors, capable of targeting both influenza and bacterial co-infections.


[h=4]KEYWORDS:[/h] antiviral peptides; gold nanoparticles; influenza virus; lytic infection; silver nanoparticles

PMID: 31165030 PMCID: PMC6541353 DOI: 10.3762/bjnano.10.104
 
Back
Top Bottom